Physician profile
Eun J Oh
NPI 1558391672
$3,025.95
in general payments reported to CMS, 2019-2025
24 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $154 · 2021: $174 · 2022: $425 · 2023: $267 · 2024: $747 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $793.18 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $655.58 | 2019-2025 | Farxiga, Tezspire, Airsupra |
| Radius Health, INC. | $240.82 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.24 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $175.05 | 2019-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $162.60 | 2023-2025 | |
| Lilly USA, LLC | $144.50 | 2019-2025 | Kisunla, Mounjaro |
| Pfizer INC. | $124.74 | 2019-2025 | |
| Abbvie INC. | $113.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $83.42 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $67.92 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $50.46 | 2019-2020 | |
| Boston Scientific Corporation | $38.79 | 2024 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $26.46 | 2020-2024 | Unithroid |
| Lundbeck LLC | $22.57 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $18.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.13 | 2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $14.97 | 2024 | Voquezna |
| Genentech USA, INC. | $14.73 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.96 | 2023 | |
| Alfasigma USA, INC. | $12.90 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.72 | 2021 | |
| Therapeuticsmd, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eun Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.